FDA Approval of Mifepristone Generic Raises Troubling Questions

Pro-lifers were disturbed when news broke of the FDA’s approval of a generic form of the “abortion pill,” mifepristone, to be produced by the aggressively pro-abortion Evita Solutions pharmaceutical company. Last week, 51 Republican senators signed on to a letter calling on the HHS and FDA to immediately act to reevaluate its decision and restrict mifepristone.

Why, pro-lifers asked, is the FDA of a purportedly pro-life administration approving a new form of the abortion pill, when it has not even completed a promised review of its health and safety guidelines? The answer, I fear, is simple: the Trump administration simply does not care about restricting mifepristone and will not act aggressively to restrict it until the political calculus changes.

JG

About the Author

John Gerardi

John Gerardi is the executive director of Right to Life of Central California in Fresno. A lawyer and the founding CEO and current development director of the Obria Medical Clinics of Central California, he hosts the radio shows and podcasts The John Gerardi Show and Right to Life Radio.

Featured Tags

Manage following

Abortion

FDA

Department of Health and Human Services

Pro-Life

Robert F. Kennedy Jr.

Pro-lifers were disturbed when news broke of the FDA’s approval of a generic form of the “abortion pill,” mifepristone, to be produced by the aggressively pro-abortion Evita Solutions pharmaceutical company. Last week, 51 Republican senators signed on to a letter calling on the HHS and FDA to immediately act to reevaluate its decision and restrict mifepristone.

Why, pro-lifers asked, is the FDA of a purportedly pro-life administration approving a new form of the abortion pill, when it has not even completed a promised review of its health and safety guidelines? The answer, I fear, is simple: the Trump administration simply does not care about restricting mifepristone and will not act aggressively to restrict it until the political calculus changes.